On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...